The estimated Net Worth of Brian Knaley is at least $125 dollars as of 20 September 2018. Brian Knaley owns over 5,000 units of ViewRay stock worth over $125 and over the last 7 years Brian sold VRAY stock worth over $0.
Brian has made over 2 trades of the ViewRay stock since 2018, according to the Form 4 filled with the SEC. Most recently Brian bought 5,000 units of VRAY stock worth $10,350 on 20 September 2018.
The largest trade Brian's ever made was buying 5,000 units of ViewRay stock on 20 September 2018 worth over $10,350. On average, Brian trades about 2,000 units every 43 days since 2018. As of 20 September 2018 Brian still owns at least 5,000 units of ViewRay stock.
You can see the complete history of Brian Knaley stock trades at the bottom of the page.
Brian's mailing address filed with the SEC is C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE, OH, 44146.
Over the last 8 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun a Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: